Darwin Global Management, Ltd.'s Form 4 filing
Ambrx Biopharma, Inc. (AMAM) · filed Mar 8, 2023
- Accession no.
- 0000902664-23-002156
- Filed
- Mar 8, 2023
- Trade date
- Feb 27-Mar 6, 2023
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 derivative transactions. It was filed 9 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Darwin Global Management, Ltd.CIK 0001839209 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | Ordinary Shares | PPurchaseAcquired | +455,889 | $5.48 | +$356,895.96 | 7,649,616 | Indirect | |
| Feb 28, 2023 | Ordinary Shares | PPurchaseAcquired | +279,699 | $6.02 | +$240,541.14 | 7,689,573 | Indirect | |
| Mar 6, 2023 | Ordinary Shares | PPurchaseAcquired | +25,305,000 | $6.50 | +$23,497,500 | 11,304,573 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.